Core Viewpoint - The company has received the drug registration certificate for the nasal spray influenza live attenuated vaccine from the National Medical Products Administration, which is expected to enhance the promotion and use of its influenza vaccine products [1] Group 1: Product Development - The vaccine is suitable for individuals aged 3 to 17 years and is administered via the nasal route, creating an initial immune barrier against influenza virus invasion in the respiratory tract [1] - The vaccine formulation has been upgraded from a freeze-dried form to a liquid form, making it more convenient for use [1] Group 2: Market Impact - The approval of this vaccine is anticipated to optimize the company's product structure and strengthen its core competitiveness in the market [1] - There is uncertainty regarding the timeline for the vaccine's market launch and sales, which presents potential investment risks [1]

Core Viewpoint - Novavax Pharmaceuticals (NVAX.O) shares rose by 15% following the announcement that its COVID-19 vaccine has been approved [1] Company Summary - Novavax has received approval for its COVID-19 vaccine, which has positively impacted its stock price, reflecting investor confidence in the company's future prospects [1] Industry Summary - The approval of COVID-19 vaccines continues to play a significant role in the pharmaceutical industry, influencing stock performance and market dynamics [1]